Switch to:
Valeant Pharmaceuticals International Inc (NYSE:VRX)
Piotroski F-Score
7 (As of Today)

Good Sign:

Piotroski F-Score of 7 is 7, indicating very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Valeant Pharmaceuticals International Inc has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

VRX' s 10-Year Piotroski F-Score Range
Min: 2   Max: 9
Current: 7

2
9

During the past 13 years, the highest Piotroski F-Score of Valeant Pharmaceuticals International Inc was 9. The lowest was 2. And the median was 5.


Definition

How is the Piotroski F-Score calculated?

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.

This Year (Sep14) TTM:Last Year (Sep13) TTM:
Net Income was 123.758 + -22.6 + 125.8 + 275.4 = $502 Mil.
Cash Flow from Operations was 279.857 + 484.3 + 376 + 618.7 = $1,759 Mil.
Revenue was 2063.805 + 1886.2 + 2041.1 + 2056.2 = $8,047 Mil.
Gross Profit was 1331.885 + 1367.8 + 1455.5 + 1495.4 = $5,651 Mil.
Average Total Assets from the begining of this year (Sep13)
to the end of this year (Sep14) was
(28204.384 + 27970.797 + 27989 + 27895.6 + 27059.6) / 5 = $27823.8762 Mil.
Total Assets at the begining of this year (Sep13) was $28,204 Mil.
Long-Term Debt was $15,584 Mil.
Total Current Assets was $4,414 Mil.
Total Current Liabilities was $3,143 Mil.
Net Income was -89.142 + -27.5 + 10.8 + -973.2 = $-1,079 Mil.

Revenue was 920.043 + 1068.4 + 1095.7 + 1541.7 = $4,626 Mil.
Gross Profit was 702.202 + 768.1 + 798 + 966.5 = $3,235 Mil.
Average Total Assets from the begining of last year (Sep12)
to the end of last year (Sep13) was
(14146.208 + 17950.379 + 17486.467 + 19782.258 + 28204.384) / 5 = $19513.9392 Mil.
Total Assets at the begining of last year (Sep12) was $14,146 Mil.
Long-Term Debt was $17,044 Mil.
Total Current Assets was $3,848 Mil.
Total Current Liabilities was $2,853 Mil.

Profitability

Q1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by total assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Valeant Pharmaceuticals International Inc's current net income (TTM) was 502. ==> Positive ==> Score 1.

Q2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by total assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Valeant Pharmaceuticals International Inc's current cash flow from operations (TTM) was 1,759. ==> Positive ==> Score 1.

Q3. Change in Return on Assets

Compare this year’s return on assets (1) to last year’s return on assets.

Score 1 if it’s higher, 0 if it’s lower.

ROA (This Year)=Net Income (TTM)/Total Assets at the Beginning of This Year (Sep13)
=502.358/28204.384
=0.01781134

ROA (Last Year)=Net Income (TTM)/Total Assets at the Beginning of Last Year (Sep12)
=-1079.042/14146.208
=-0.07627783

Valeant Pharmaceuticals International Inc's return on assets of this year was 0.01781134. Valeant Pharmaceuticals International Inc's return on assets of last year was -0.07627783. ==> This year is higher. ==> Score 1.

Q4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Valeant Pharmaceuticals International Inc's current net income (TTM) was 502. Valeant Pharmaceuticals International Inc's current cash flow from operations (TTM) was 1,759. ==> 1,759 > 502 ==> CFROA > ROA ==> Score 1.

Funding

Q5. Change in Gearing or Leverage

Compare this year’s gearing (long-term debt divided by average total assets) to last year’s gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep14)=Long-Term Debt/Average Total Assets from Sep13 to Sep14
=15584.3/27823.8762
=0.56010528

Gearing (Last Year: Sep13)=Long-Term Debt/Average Total Assets from Sep12 to Sep13
=17043.75/19513.9392
=0.87341412

Valeant Pharmaceuticals International Inc's gearing of this year was 0.56010528. Valeant Pharmaceuticals International Inc's gearing of last year was 0.87341412. ==> This year is lower or equal to last year. ==> Score 1.

Q6. Change in Working Capital (Liquidity)

Compare this year’s current ratio (current assets divided by current liabilities) to last year’s current ratio.

Score 1 if this year'’s current ratio is higher, 0 if it’s lower

Current Ratio (This Year: Sep14)=Total Current Assets/Total Current Liabilities
=4413.7/3143.3
=1.40416123

Current Ratio (Last Year: Sep13)=Total Current Assets/Total Current Liabilities
=3848.363/2853.082
=1.34884416

Valeant Pharmaceuticals International Inc's current ratio of this year was 1.40416123. Valeant Pharmaceuticals International Inc's current ratio of last year was 1.34884416. ==> This year's current ratio is higher. ==> Score 1.

Q7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Valeant Pharmaceuticals International Inc's number of shares in issue this year was 341.3. Valeant Pharmaceuticals International Inc's number of shares in issue last year was 333.6. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Q8. Change in Gross Margin

Compare this year’s gross margin (gross profit divided by sales) to last year’s.

Score 1 if this year’s gross margin is higher, 0 if it’s lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=5650.585/8047.305
=0.7021711

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=3234.802/4625.843
=0.69928919

Valeant Pharmaceuticals International Inc's gross margin of this year was 0.7021711. Valeant Pharmaceuticals International Inc's gross margin of last year was 0.69928919. ==> This year's gross margin is higher. ==> Score 1.

Q9. Change in asset turnover

Compare this year’s asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year’s asset turnover ratio.

Score 1 if this year’s asset turnover ratio is higher, 0 if it’s lower

Asset Turnover (This Year)=Revenue (TTM)/Total Assets at the Beginning of This Year (Sep13)
=8047.305/28204.384
=0.28532107

Asset Turnover (Last Year)=Revenue (TTM)/Total Assets at the Beginning of Last Year (Sep12)
=4625.843/14146.208
=0.32700233

Valeant Pharmaceuticals International Inc's asset turnover of this year was 0.28532107. Valeant Pharmaceuticals International Inc's asset turnover of last year was 0.32700233. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score=Q1+Q2+Q3+Q4+Q5+Q6+Q7+Q8+Q9
=1+1+1+1+1+1+0+1+0
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Valeant Pharmaceuticals International Inc has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.


Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Related Terms

Net Income, Cash Flow from Operations, Revenue, Gross Profit, Total Assets, Long-Term Debt, Total Current Assets, Total Current Liabilities


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.

Valeant Pharmaceuticals International Inc Annual Data

Dec04Dec05Dec06Dec07Dec08Dec09Dec10Dec11Dec12Dec13
Q1 1111110100
Q2 1111111111
Q3 1100100100
Q4 1111111111
Q5 1111000100
Q6 1110001011
Q7 1100110010
Q8 0110100110
Q9 0100111011
F-score 7964754664

Valeant Pharmaceuticals International Inc Quarterly Data

Jun12Sep12Dec12Mar13Jun13Sep13Dec13Mar14Jun14Sep14
Q1 1100000001
Q2 1111111111
Q3 1000000001
Q4 1111111111
Q5 0000000001
Q6 1110101101
Q7 1111000000
Q8 1111100001
Q9 0111111110
F-score 7765534437
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK